financetom
Business
financetom
/
Business
/
Arista Networks Insider Sold Shares Worth $9,689,373, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Arista Networks Insider Sold Shares Worth $9,689,373, According to a Recent SEC Filing
Mar 14, 2024 6:39 AM

09:12 AM EDT, 03/14/2024 (MT Newswires) -- Kenneth Duda, Director, CTO and SVP Software Eng., on March 11, 2024, sold 36,000 shares in Arista Networks ( ANET ) for $9,689,373. Following the Form 4 filing with the SEC, Duda has control over a total of 1,090,326 shares of the company, with 3,244 shares held directly and 1,087,082 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1596532/000159653224000107/xslF345X03/edgardoc.xml

Price: 280.83, Change: +0.12, Percent Change: +0.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission
Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission
Oct 13, 2025
09:45 AM EDT, 10/13/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Monday it completed a positive pre-biologics license application meeting with the US Food and Drug Administration for its drug candidate delpacibart zotadirsen, or del-zota, to potentially treat Duchenne muscular dystrophy patients with exon 44 mutations. The company said it now plans to submit the BLA in Q1...
Palvella Receives Second Year of FDA Grant Funding for Phase 3 Qtorin Trial
Palvella Receives Second Year of FDA Grant Funding for Phase 3 Qtorin Trial
Oct 13, 2025
10:09 AM EDT, 10/13/2025 (MT Newswires) -- Palvella Therapeutics ( PVLA ) said Monday it has received the second year of funding under its US Food and Drug Administration Office of Orphan Products Development grant, supporting the company's ongoing phase 3 trial evaluating Qtorin 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. The grant provides up to...
Form 8.3 - Just Group plc
Form 8.3 - Just Group plc
Oct 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Codelco lifts El Teniente loss estimate, copper output target intact
Codelco lifts El Teniente loss estimate, copper output target intact
Oct 13, 2025
LONDON (Reuters) - Codelco's copper losses from the accident at its El Teniente mine are likely to be 45% higher than previously estimated, but Chairman Maximo Pacheco still expects the world's largest copper miner to slightly increase output this year. Loss of output from Chile's El Teniente along with other disruptions including at Freeport-McMoRan's ( FCX ) Grasberg mine in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved